Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 19, 2014 08:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals to Present Clinical and Biomarker Data on Novel Antibody Therapeutics at the ESMO 2014 Congress

CAMBRIDGE, Mass., Sept. 19, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced it will present clinical data on three novel antibody cancer therapeutics at the ESMO...
August 11, 2014 07:05 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Announces Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients With Advanced HER2-Positive Breast Cancer to Support Application for Accelerated Approval

CAMBRIDGE, Mass., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the initiation of a global, open-label, randomized Phase 2 trial of MM-302, a...
August 11, 2014 07:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Reports Second Quarter 2014 Financial Results

CAMBRIDGE, Mass., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...
August 04, 2014 16:01 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Announces Timing of Second Quarter 2014 Investor Conference Call

CAMBRIDGE, Mass., Aug. 4, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Second Quarter 2014 Investor Conference Call and webcast...
June 25, 2014 16:05 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Presents Data From Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer

MM-398 in combination with 5-fluorouracil and leucovorin shows statistically significant improvement in overall survival, progression free survival and overall response rate in patients with...
June 19, 2014 16:14 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals to Regain Worldwide Rights to Develop and Commercialize MM-121

Merrimack to Pursue Registration Path for MM-121 and Partnership Opportunities Top Line Results Released From Final Phase 2 Study in the Collaboration CAMBRIDGE, Mass., June 19, 2014 (GLOBE...
June 17, 2014 08:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Announces Oral Presentation of Additional Data Results in Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer

CAMBRIDGE, Mass., June 17, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that results of the successful Phase 3 NAPOLI-1 study in metastatic pancreatic cancer...
June 02, 2014 16:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs at the 2014 ASCO Annual Meeting

CHICAGO, June 2, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Phase 1 clinical data from studies of MM-151, MM-141, MM-111 and MM-121 was presented at...
June 02, 2014 08:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Identifies Heregulin as Patient Response Biomarker for MM-121 and Standard of Care Therapy Across Multiple Cancers

Studies indicate that 30-50 percent of patients most at risk of progression may benefit from MM-121 Data presented at the 2014 ASCO Annual Meeting from three Phase 2 studies in metastatic lung,...
May 27, 2014 08:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference

CAMBRIDGE, Mass., May 27, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the Jefferies 2014...